Recursion Pharmaceuticals short interest was 35.49% of the float on April 15th, according to new data we received from Benzinga. Short interest totaled 174,397,876 shares, which was an increase of 0.27% from March 31st.
It is estimated that it would take 17.12 days for short sellers to buy back their shares, with current trading volumes.
Recursion Pharmaceuticals Hedge Fund Activity
We have seen 199 institutional investors add shares of Recursion Pharmaceuticals stock to their portfolio, and 131 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MUBADALA INVESTMENT CO PJSC removed 12,985,927 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $53,112,441
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 12,712,693 shares (-75.7%) from their portfolio in Q4 2025, for an estimated $51,994,914
- NVIDIA CORP removed 7,706,363 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $31,519,024
- VANGUARD GROUP INC added 7,407,606 shares (+18.6%) to their portfolio in Q4 2025, for an estimated $30,297,108
- BLACKROCK, INC. added 7,127,014 shares (+22.5%) to their portfolio in Q4 2025, for an estimated $29,149,487
- STATE STREET CORP added 7,064,963 shares (+38.7%) to their portfolio in Q4 2025, for an estimated $28,895,698
- ARK INVESTMENT MANAGEMENT LLC added 3,771,357 shares (+11.2%) to their portfolio in Q4 2025, for an estimated $15,424,850
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Recursion Pharmaceuticals Insider Trading Activity
Recursion Pharmaceuticals insiders have traded $RXRX stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- BLAKE BORGESON has made 0 purchases and 5 sales selling 860,000 shares for an estimated $3,525,800.
- CHRISTOPHER GIBSON has made 0 purchases and 11 sales selling 440,000 shares for an estimated $1,790,400.
- NAJAT KHAN (CEO and President) has made 0 purchases and 2 sales selling 152,701 shares for an estimated $643,251.
- BEN R TAYLOR (Chief Financial Officer) has made 0 purchases and 3 sales selling 42,765 shares for an estimated $157,703.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Recursion Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $RXRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 12/17/2025
To track analyst ratings and price targets for Recursion Pharmaceuticals, check out Quiver Quantitative's $RXRX forecast page.
Recursion Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $RXRX recently. We have seen 4 analysts offer price targets for $RXRX in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Priyanka Grover from JP Morgan set a target price of $10.0 on 04/30/2026
- Michael Ryskin from B of A Securities set a target price of $6.0 on 02/26/2026
- Gil Blum from Needham set a target price of $8.0 on 02/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
